The right LIMS for cell and gene therapy should support complete traceability, flexible workflows, and strict process control across manufacturing and quality operations. Choosing a LIMS for CGT requires evaluating how well it can support the unique operational demands of these environments, even though the underlying regulatory requirements are largely the same as other GMP industries.
Patient-specific manufacturing, evolving analytical methods, production-driven environmental monitoring programs, and compressed timelines to IND and BLA submissions create an environment where flexibility, traceability, and adaptability are essential. The result is a LIMS selection process with higher stakes and greater complexity than many organizations initially anticipate.
Most CGT teams arrive at this decision from one of three places:
- 1. Paper and spreadsheets that have hit their scale limit – the most common starting point
- 2. An electronic lab notebook (ELN) that wasn't designed for GMP workflows beyond research and early clinical stages
- 3. A homegrown system that worked perfectly, until it didn't
This guide is designed for quality control, operations, IT, and compliance leaders at CGT organizations evaluating a LIMS. Rather than serving as a vendor comparison matrix, it provides a framework for asking the right questions, interpreting the answers, and making informed decisions based on the unique needs of your organization.
What makes cell and gene therapy manufacturing different from other GMP manufacturing?
Cell and gene therapy manufacturing differs fundamentally from traditional pharmaceutical production. Rather than operating as a highly standardized, repeatable process, CGT is defined by biological variability, patient- or donor-specific inputs, and rapidly evolving scientific methods. These characteristics place unique demands on data management, traceability, and regulatory documentation which are requirements that directly shape LIMS selection.
At the same time, CGT is not a single, uniform manufacturing model. The term spans multiple therapeutic approaches, each with distinct operational realities and system requirements.
- - Autologous cell therapies: Manufacturing depends on an unbroken chain of identity from apheresis to infusion. With one patient linked to one batch, every data point has direct clinical significance, making complete traceability essential for patient safety.
- - Viral vector and gene therapies: Assays, process parameters, and product specifications often evolve throughout clinical development. A LIMS must support ongoing process and method changes without creating unnecessary validation overhead.
- - Allogeneic and iPSC-derived therapies: Success depends on scaling production while maintaining consistency. Organizations need a LIMS that supports master cell bank management, reproducible manufacturing, and deep lot-level traceability.
- - Cell and gene therapy CDMOs: Supporting multiple clients, programs, and therapeutic modalities requires configurable workflows, data segregation, and rapid onboarding of new programs without repeated revalidation or custom development.
Despite these differences, all CGT organizations share a common underlying reality: high data complexity, significant regulatory documentation requirements, and manufacturing workflows that continue to evolve as the science advances. The challenge is not only managing today’s processes, but also adapting to tomorrow’s changes without compromising traceability or compliance.
Taken together, these factors make LIMS selection in CGT less about feature comparison and more about alignment to the organization’s underlying manufacturing model, quality strategy, and growth trajectory.
Which enterprise LIMS is best for cell and gene therapy manufacturing?
Labbit
Labbit is a graph-native LIMS designed for the data complexity, regulatory documentation requirements, and evolving manufacturing workflows common in cell and gene therapy. Rather than storing laboratory data in relational tables, Labbit captures relationships between patients, samples, materials, batches, operators, instruments, and results as a native property of the data model, an architectural choice with implications for how traceability, investigation, and process data are accessed as programs grow and processes change.
Strengths
- - Graph-native architecture means chain-of-identity, chain-of-custody, and end-to-end lineage are inherent properties of the data model rather than assembled at query time, providing a continuously navigable audit record across the manufacturing lifecycle.
- - Configuration sits above the validated core, meaning workflows, entities, and data models can be modified without schema changes or full-system revalidation. Changes are versioned and scoped, limiting revalidation to only what was touched.
- - Compliance controls are enforced at the point of execution, blocking invalid materials, gating progression on required approvals, and enforcing eSignatures within controlled workflow steps.
Considerations
- - Labbit is an enterprise platform best suited to organizations with complex, interconnected workflows. Organizations with simpler or more standardized operations may find it more than what they actually need.
- - Getting the most out of implementation requires upfront investment in business process mapping to understand how laboratory, manufacturing, and quality processes co-mingle. Organizations with limited bandwidth for that discovery work may find a more prescriptive, off-the-shelf system a better fit.
L7 Informatics
L7 Informatics is a workflow-driven platform built for regulated life sciences, with integrated LIMS, MES, ELN, and electronic batch record (EBR) capabilities in a single system, a design that is particularly relevant in CGT environments where QC and manufacturing execution are tightly coupled.
Strengths
- - Unified LIMS, MES, ELN, and EBR in a single platform reduces the need for cross-system integration in environments where QC and manufacturing execution are tightly coupled.
- - Configurable workflows can flex as processes evolve across clinical phases and into commercialization.
Considerations
- - Relational SQL architecture means chain-of-custody and end-to-end lineage across patients, samples, materials, and batches may need to be reconstructed from audit log tables at query time.
- - Modifying data models or metadata structures after go-live requires schema changes. In a validated GMP environment, schema changes typically trigger formal change control events and revalidation cycles, creating some friction in CGT programs where process parameters and metadata models tend to evolve over time.
LabVantage
LabVantage is one of the most established names in enterprise LIMS, and frequently appears on CGT shortlists due to its broad pre-built functionality, long track record, and perceived vendor stability in regulated environments. Its strength is depth across general laboratory and QC workflows, though that breadth comes with tradeoffs worth examining in CGT-specific contexts, where data complexity is high, traceability requirements are stringent, and processes continue to evolve as the science advances.
Strengths
- - Broad pre-built functionality across laboratory and QC workflows provides an enterprise-grade foundation without starting from scratch.
- - More configurable than many legacy LIMS platforms, with the ability to support complex, multi-domain laboratory environments.
Considerations
- - CGT workflows can require meaningful configuration to model accurately, particularly for processes where entities transform, split, or change state across manufacturing steps. It's worth understanding how well the data hierarchy maps to your specific workflows.
- - As CGT processes evolve across clinical phases, changes may carry validation implications. LabVantage manages updates across separate systems via manual application, so how validation status is tracked and maintained over time should be part of evaluation.
- - Because data is stored across relational tables, end-to-end lineage may require additional queries or reporting logic to surface a complete view, and supporting chain-of-identity and chain-of-custody traceability typically involves configuration across multiple system components. Both are worth exploring in the context of your audit and inspection requirements.
Sapio Sciences
Sapio Sciences is a unified LIMS and ELN platform with a modern user experience and a strong emphasis on configurability. Its consolidation of LIMS and ELN in a single platform reduces the need for separate systems across R&D and early clinical operations.
Strengths
- - Clean, modern interface that can be more appealing to end users than legacy LIMS platforms with more complex or dated designs.
- - Combined LIMS and ELN capabilities in a single platform support continuity between experimental documentation and structured sample workflows, reducing the need for separate systems across R&D and early clinical operations.
Considerations
- - Despite its modern interface, some reviewers note a steeper learning curve than the UX might initially suggest.
- - Built on a relational data architecture, introducing new entity types or relationships as CGT data models evolve may require schema-level changes, which has implications for validation status in a GMP-regulated environment.
- - Because relationships across samples, materials, manufacturing steps, and results are stored in relational tables rather than natively connected, surfacing complete end-to-end lineage – including chain-of-identity and chain-of-custody – may require additional queries or reporting logic to assemble.
LabWare
LabWare is one of the longest-standing enterprise LIMS platforms in regulated life sciences, frequently appearing on CGT shortlists alongside LabVantage due to its market presence, established validation history, and reputation for configurability that can accommodate complex workflows.
Strengths
- - Long track record across regulated GMP environments in pharmaceutical and biotechnology manufacturing, with an established validation history that carries weight in procurement processes.
- - Broad configurability that can accommodate a wide range of laboratory workflows, particularly in organizations with internal IT or development resources available to support implementation and ongoing maintenance.
- - MES integration available through a partnership with Körber, providing a path to connect laboratory and manufacturing execution for CGT environments where end-to-end coverage is a requirement.
Considerations
- - Configurability is largely delivered through LIMS Basic scripting, meaning workflow changes typically involve developer resources, which is something to factor into resourcing plans for CGT environments where processes can evolve frequently across clinical phases.
- - Because changes are scripting-dependent, each modification carries its own validation scope. In GMP environments where process parameters and assay requirements change regularly, this can mean frequent, discrete validation events that accumulate over time.
- - Customization layered over time can introduce technical debt that makes upgrades increasingly involved, with regression testing required against accumulated scripts and configurations. It’s worth understanding how upgrade management would work before committing to a heavily customized implementation.
- - As with other SQL-based systems, relationships across patients, samples, materials, and manufacturing steps are stored in relational tables rather than natively connected, so surfacing complete end-to-end lineage may require additional queries or reporting logic to assemble a complete, audit-ready record.
Benchling LIMS
Benchling is the dominant ELN platform in life sciences R&D, with deep penetration in CGT research and process development environments. Its LIMS capabilities extend the platform into structured sample management and operational data capture. In CGT evaluations, Benchling most often appears as an incumbent system already embedded in preclinical and early clinical workflows, with the central question being whether it can continue to serve the organization as manufacturing requirements mature under GMP.
Strengths
- - Widely adopted across CGT research for molecular biology, sequence design, and experimental documentation, meaning data, processes, and user familiarity are often already established when it enters a LIMS evaluation.
- - Highly optimized for R&D workflows including molecular design, sequence management, and process development data capture, making it particularly effective for preclinical and early clinical stage organizations.
- - Benchling’s Validated Cloud offering provides a structured path for organizations moving toward more regulated contexts, helping reduce perceived friction when extending existing usage into compliance-sensitive environments.
Considerations
- - Benchling's workflow model is optimized for flexible, collaborative research rather than controlled, sequential manufacturing execution. In GMP contexts, native support for structured task handoffs, queue-based execution, and tightly governed operational workflows may be limited.
- - Sample tracking is well suited to experimental lineage and process development, but the degree to which it meets GMP chain-of-custody and chain-of-identity requirements in manufacturing contexts is worth exploring directly.
- - The Validated Cloud supports compliance packaging and controlled deployment, but does not fundamentally alter the underlying workflow model or manufacturing-oriented capabilities of the platform.
Conclusion: Choosing the Right Foundation
Every vendor in this guide is a credible option for CGT organizations, and each has strengths that may make it the right fit in certain situations. But features alone don't tell the whole story.
Cell and gene therapy manufacturing evolves rapidly, with changing methods, workflows, and product requirements. The LIMS you choose needs to adapt without creating unnecessary validation effort, compromising traceability, or making every change a structural project. Architecture can play an important role in determining how well a platform supports that evolution over time.
If you're evaluating LIMS platforms for cell and gene therapy, our CGT LIMS Buyer’s Guide goes deeper, providing the questions to ask vendors and the key capabilities and considerations to explore during your evaluation.
Download the CGT LIMS Buyer’s Guide
